Pharma and GLP-1 stocks at the IRA Round 1 cutover: 35 names across 5 layers, 3 portfolios — June 2026 guide for Indian investors

Five events have rewritten the US pharma equity setup in twelve months:

January 1, 2026 (IRA Round 1 effective): The first ten Medicare-negotiated drug prices took effect. Discounts of 38% to 79% off list. The list includes Eliquis (BMS/Pfizer), Stelara (JNJ), Xarelto (JNJ/Bayer), Januvia (MRK), Jardiance (LLY/BI), Enbrel (AMGN), Imbruvica (ABBV/JNJ), Farxiga (AZN), Entresto (NVS), Fiasp/NovoLog (NVO). Stelara dropped 66%. Januvia dropped 79%. Imbruvica dropped 38% (the smallest).

Round 2 effective January 1, 2027: Announced November 2025. Ozempic, Wegovy, and Rybelsus included — 71% Medicare discount. Round 2 negotiated price for Ozempic ~$274/month from $959 list.

April 1, 2026 (Foundayo FDA approval): Eli Lilly's orforglipron — the first oral small-molecule GLP-1 approved for obesity — got FDA clearance under the 50-day National Priority Voucher review. Launched April 6 via LillyDirect. Self-pay $149/month lowest dose; $25/month commercial copay; $50/month Medicare Part D from July 1, 2026.

May 21, 2026 (TRIUMPH-1 readout): Lilly's retatrutide (GIP/GLP-1/glucagon triple agonist) Phase 3 delivered 70.3 pounds average weight loss at 12 mg / 80 weeks — the highest weight loss ever reported in a Phase 3 obesity trial. NDA filing targeted Q4 2026; FDA approval expected late 2027 to early 2028.

April 2, 2026 EO (Trump pharma tariff): 100% tariff on patented pharmaceuticals from countries not signing MFN/reshoring agreements. Generics exempted. Effective July 31, 2026 (large companies) / September 29, 2026 (small). 17 manufacturer MFN agreements by April 2026 covering 86% of branded drug market. TrumpRx.gov direct-to-consumer site launched February 5, 2026.

Together these events have produced the cleanest "structural revenue reset" in pharma in two decades. The complication: the GLP-1 trade is a duopoly that drove Mounjaro+Zepbound to $12.9 billion in a single quarter — and the rest of pharma is a mix of IRA-impaired franchises and biotech innovation that needs to absorb both Round 2 GLP-1 negotiation in 2027 and the LOE wave hitting Keytruda (2028) and Eliquis (2028).

This guide is for the Indian-resident investor who wants real US healthcare exposure when domestic Indian pharma (Sun, Dr Reddy's, Cipla, Glenmark, Zydus) has no commercial-scale US GLP-1 footprint despite launching generic semaglutide in India in March 2026.

What this guide is and isn't

It is: 35 names organized by what 2026 actually rewards, one verdict per name, three model portfolios, and an honest call on which IRA-impaired names are dead weight versus which compensate through biosimilar defense or pipeline.

It is not: "buy LLY and forget." Not pretending Round 2 IRA isn't a headwind. Not assuming Trump MFN deals stay voluntary indefinitely.

A note on data. Every revenue, FDA action, IRA negotiated price, and LOE date traces to a primary source — SEC filings, CMS published documents, FDA approval letters, Q1 2026 earnings calls. Where verification wasn't possible the article says "not separately disclosed."

The framework: IRA + MFN + Tariffs reshape the entire revenue base

The GLP-1 duopoly. LLY Q1 2026 revenue $19.8 billion (+56% YoY), EPS $8.26 (+170%). Mounjaro+Zepbound combined $12.9 billion (~65% of LLY total). NVO Q1 2026 revenue ~$14.97 billion (+18% CER). Wegovy injectable DKK 18.2B (~$2.6B, +12%); Wegovy pill DKK 2.26B (~$354M) in its debut quarter. No other public-market name has commercial GLP-1 revenue. Roche's CT-388 (enicepatide), Amgen's MariTide, and Pfizer's Metsera pipeline are all 2027-2028+ launches.

Round 1 IRA hits the diversified large-caps. BMY Eliquis, JNJ Stelara + Xarelto, MRK Januvia, LLY Jardiance, AMGN Enbrel, ABBV Imbruvica, AZN Farxiga, NVS Entresto, NVO Fiasp. The single biggest concentrated hit: BMY/Pfizer Eliquis at ~$4.1B in Q1 2026 facing -56% Medicare discount with US generic entry April 1, 2028.

Round 2 hits GLP-1 in 2027. Ozempic+Wegovy+Rybelsus -71% Medicare discount effective January 1, 2027. NVO bears this most directly; LLY's Zepbound is not yet on Round 2 list but tirzepatide will likely be on Round 3 or 4.

The Keytruda 2028 cliff is the dominant LOE story. MRK Q1 2026 Keytruda revenue $8.03 billion (+12% YoY). Subcutaneous Keytruda Qlex launched late 2025 / Q1 2026: $128M in debut quarter; permanent J-code April 1, 2026; EC approval Q1 2026. The Qlex strategy is to migrate the franchise to SC injection before IV LOE.

Five layers, ranked by 2026 dollar opportunity for Indian retail:

Layer	What it is	2026 read
1. GLP-1 leaders	LLY, NVO + (AMGN, RHHBY, PFE pipeline)	Duopoly; Foundayo + retatrutide are LLY moats
2. Big Pharma diversified	JNJ, MRK, ABBV, AZN, NVS, GSK, SNY	IRA Round 1 effective; LOE 2028 wave
3. US biotech innovators	VRTX, REGN, GILD, BMY, MRNA, BIIB	Mixed — VRTX and GILD strong, BMY/MRNA pressured
4. Oncology + cell/gene	CRSP, EDIT, NTLA, BNTX, CYTK	Casgevy ramping at VRTX; mostly speculative
5. Medical devices + diagnostics	ISRG, SYK, BSX, MDT, EW, DXCM, TMO, DHR	Procedure recovery story; BSX standout

Verdict format:

Verdict — [Action]: [Reason]. [Caveat].

---

Layer 1 — GLP-1 leaders

LLY — Eli Lilly

Q1 2026 (reported April 30, 2026): revenue $19.8 billion (+56% YoY). Volume +45%; price flat to slightly down. EPS $8.26 (+170% YoY). Mounjaro WW $8.7 billion (+125% YoY); US $4.2B (+59%); ex-US $4.4B (+267%). Zepbound WW $4.2 billion (+80% YoY). Mounjaro+Zepbound combined $12.9 billion = ~65% of LLY total revenue.

Foundayo (orforglipron) FDA approved April 1, 2026 under National Priority Voucher. Self-pay $149/month lowest dose; $25/month commercial copay; $50/month Medicare Part D from July 1, 2026. Will be included Q2 2026 onwards. Orforglipron T2D filing in 2026.

Retatrutide TRIUMPH-1 (May 21, 2026): 70.3 lb average weight loss at 12 mg / 80 weeks — highest in any Phase 3 obesity trial. NDA filing Q4 2026; FDA approval late 2027/early 2028.

IRA exposure: Jardiance MFP $197/30-day from $573 list — 66% discount effective January 1, 2026. Co-marketed with Boehringer; meaningful but dwarfed by Mounjaro/Zepbound.

FY 2026 guide raised: Revenue $82-85B; EPS $20.78-$22.28. $27 billion US capacity expansion plan; Huntsville AL orforglipron API plant under construction.

Forward P/E ~32-35× FY26e.

Catalyst: Foundayo Q2 launch ramp; retatrutide NDA Q4 2026; tirzepatide HFpEF FDA decision (EMA CHMP positive January 2026).

Risk: Foundayo $149/month tells the market self-pay/MFN deflation is real; Mounjaro pricing compression visible in Q1; IRA Round 3/4 will likely include tirzepatide.

Verdict — Core buy: The single cleanest GLP-1 thesis with three discrete catalysts in the next 12 months (Foundayo ramp, retatrutide NDA, HFpEF approval). Premium multiple justified.

NVO — Novo Nordisk (ADR)

Q1 2026 (reported May 6, 2026): revenue ~$14.97 billion (+18% CER). Beat consensus by ~34%. Wegovy injectable DKK 18.2B (~$2.6B, +12% YoY). Wegovy pill DKK 2.26B (~$354M) in DEBUT QUARTER (US launch January 2026) — ~1.3 million prescriptions, far above $170M consensus. Ozempic -8% YoY (supply normalization, MFN pricing, Round 2 anticipation).

CagriSema (semaglutide + cagrilintide): NDA filed with FDA for obesity. REDEFINE 1: 22.7% weight loss at 68 weeks. Lower than internally hoped 25% but still best-in-class injectable. FDA action expected 2026.

GLP-1 supply RESOLVED: FDA declared semaglutide injection shortage resolved February 2025; tirzepatide shortage resolved October 2024. Compounded GLP-1 from 503A/503B channels effectively wound down.

IRA Round 2: Ozempic+Wegovy+Rybelsus -71% Medicare discount effective January 1, 2027. Round 2 Ozempic ~$274/month from $959. The biggest looming overhang for NVO.

MFN deal: Novo signed TrumpRx/MFN deal Q4 2025. Wegovy cash NovoCare ~$349/month some doses.

Capacity: $6B Kalundborg Denmark API expansion; $2.3B France manufacturing upgrade.

Forward P/E ~17-19× FY26e — heavily compressed vs LLY due to Round 2 IRA + competitive losses.

Catalyst: CagriSema FDA decision; Wegovy pill ex-US launches; amycretin Phase 2.

Risk: Round 2 IRA hits all three semaglutide products simultaneously January 1, 2027; CagriSema missed internal 25% target; LLY's Foundayo is a direct Wegovy-pill competitor at lower self-pay.

Indian retail access: NYSE ADR; Denmark 27% WHT reducible to 15% under DTAA.

Verdict — Hold: Multiple compression already reflects Round 2 IRA risk. The Wegovy pill DKK 2.26B debut quarter is a real positive, but the LLY franchise is structurally ahead.

AMGN — Amgen

MariTide (monthly GIP antagonist/GLP-1 agonist): Phase 2 obesity: up to 20% weight loss; T2D: 17% weight loss + 2.2% A1C reduction. Continued without plateau at 52 weeks. NEJM published. Phase 3 MARITIME program initiated 2025; topline obesity data expected late 2026/2027. Differentiation: monthly cadence vs weekly tirzepatide/semaglutide.

Pavblu (aflibercept biosimilar — Eylea biosimilar): Launched at-risk October 2024; $700M in 2025 sales.

IRA Round 1: Enbrel MFP $2,335 / -67% discount effective January 1, 2026.

Forward P/E ~14-15× FY26e — low among large-cap pharma reflecting IRA + biosimilar erosion.

Verdict — Hedge: MariTide is the binary call option — monthly cadence needs to demonstrate competitive efficacy vs Zepbound/Wegovy in Phase 3. Size 2-3% as GLP-1 hedge.

PFE — Pfizer

Q1 2026: revenue $14.45B; adjusted EPS $0.75 (beat). GLP-1 status: danuglipron DISCONTINUED April 2025 after single asymptomatic patient liver injury. Pipeline replacement: Metsera acquisition; first GLP-1 approval target 2028.

IRA: Eliquis MFP $231 from $521 list (-56%) effective January 1, 2026 — co-marketed with BMS, half-share for Pfizer.

Forward P/E ~9-11× FY26e — deeply value-tilted.

Verdict — Avoid: No credible GLP-1 path before 2028; Eliquis IRA + COVID franchise structural decline. Cheap multiple compensates but better value elsewhere.

RHHBY — Roche Holding (OTC ADR)

Enicepatide (CT-388, dual GLP-1/GIP): 22.5% placebo-adjusted weight loss at 24 mg / 48 weeks in Phase 2; no plateau. Two Phase 3 trials initiated Q1 2026. Petrelintide (amylin) + enicepatide combination Phase 2 first patient mid-2026. CT-996 oral GLP-1 Phase 2 readout before end-2026.

Vabysmo (anti-VEGF): competing with Eylea — growth tracking ahead as REGN's Eylea biosimilars erode.

Forward P/E ~15-17× FY26e.

Indian retail access: OTC ADR; less liquid; Swiss 35% WHT reducible to 10% under DTAA.

Verdict — Hedge: 3-4 years behind LLY+NVO but post-Carmot pipeline is real. Vabysmo growth offsets some R&D risk. Size 1-2% as obesity diversifier.

---

Layer 2 — Big Pharma diversified (IRA Round 1 effective)

JNJ — Johnson & Johnson

Q1 2026: revenue $24.1 billion (+6.4% YoY). ~540 bps Stelara biosimilar headwind. Innovative Medicine $15.4B (+7.4% operationally). MedTech ~$8.7B (+4.6% operationally). Darzalex $3.96B (+22.5%). Carvykti $597M (+62% YoY) — on pace >$2.4B FY26 run rate. Stelara -61.7% YoY.

IRA Round 1: Stelara MFP $4,695 (from $13,836, -66%); Xarelto MFP $197 (from $517, -62%) — both effective January 1, 2026.

FY 2026 guide raised: operational sales growth 5.9-6.9%; midpoint $100.2B.

Forward P/E ~15-16× FY26e.

Verdict — Add: Best of the diversified Big Pharma by Q1 print quality. MedTech (Abiomed/Shockwave) + Innovative Medicine ex-Stelara grew double digits. The dominant 2026 narrative (Stelara cliff) is already priced.

MRK — Merck

Q1 2026: revenue $16.29B (+5% YoY). Keytruda $8.03B (+12% YoY). Keytruda Qlex SC $128M in debut quarter; permanent J-code April 1, 2026; EC approval Q1 2026. Cidara acquisition Q1 2026: $9B one-time charge.

IRA Round 1: Januvia MFP -79% discount (deepest in Round 1) effective January 1, 2026.

Keytruda IV LOE 2028 — the dominant overhang. Qlex SC + earlier-line expansion is the LOE defense playbook.

Forward P/E ~10-11× FY26e — deeply value, Keytruda LOE compression.

Verdict — Hold: Qlex SC migration strategy is the right move but 2028 LOE means ~$30B+ at risk. Cheap multiple compensates but better value in JNJ or LLY.

ABBV — AbbVie

Q1 2026: revenue ~$15.0B (+12.4% YoY). Skyrizi $4.483B (+30.9%); FY26 guide raised to ~$21.6B. Rinvoq $2.119B (+23.3%); FY26 guide raised to ~$10.2B. Humira $688M (-38.6%) — sub-$3B annualized.

IRA: Imbruvica MFP $9,319 (from $14,934, -38%) effective January 1, 2026 — smallest Round 1 discount.

Forward P/E ~16-17× FY26e.

Verdict — Add: Skyrizi+Rinvoq combined growth ~+27% YoY at $6.6B Q1 run rate is the cleanest immunology compounder. Humira erosion priced in.

AZN — AstraZeneca (ADR)

Q1 2026: revenue $15.3B (+8% reported). Oncology $6.8B (+16% CER). Tagrisso $1.833B (+9%). Enhertu (with Daiichi): AZN-recorded $831M (+40%); combined $1.422B Q1. Farxiga MFP $178.50 (-68%) effective January 1, 2026; CVRM division -7% CER.

Forward P/E ~16-17× FY26e.

Indian retail access: NASDAQ ADR; UK 0% WHT for residents claiming DTAA.

Verdict — Add: Enhertu trajectory is the standout positive. UK 0% WHT is the structural Indian-retail advantage.

NVS — Novartis (ADR)

Q1 2026: revenue $13.113B (-1% USD / -5% CER). Core OI -14% CER. Kisqali $1.516B (+55% CER) standout. Pluvicto $642M (+70%). Entresto MFP $295 (-53%) effective January 1, 2026.

Forward P/E ~16-17× FY26e.

Indian retail access: NYSE ADR; Switzerland 35% WHT reducible to 10% under DTAA.

Verdict — Hold: Kisqali + Pluvicto growth is real but Entresto IRA + Core OI -14% CER signals near-term pressure.

GSK — GSK plc (ADR)

Q1 2026: revenue £7.6B (+5% YoY). Shingrix £1B+ (+20% YoY) record. Trelegy £0.6B stable. Core OP +10%; EPS +9%.

Forward P/E ~10-11× FY26e — deeply value.

Verdict — Hold: Shingrix dominance is real but General Medicines decline limits upside. Cheap value play.

SNY — Sanofi (ADR)

Q1 2026: revenue €10.509B (+13.6% CER). Dupixent €4.17B (+30.8%) — tracking ~€20B annualized. Beyfortus €284M.

Forward P/E ~13-14× FY26e.

France 25% WHT reducible to 10% under DTAA.

Verdict — Add: Dupixent at €20B annualized run rate is the standout franchise. Beyfortus RSV is incremental.

---

Layer 3 — US biotech innovators

VRTX — Vertex Pharmaceuticals

Q1 2026: revenue $2.99B (+8% YoY). Net income $1.03B; diluted EPS $4.02. CF franchise: Trikafta/Kaftrio $2.355B; Alyftrek (next-gen) $424.4M (vs $53.9M PY) — rapid switch. Casgevy $43M; >500 patients globally initiated treatment journey. Journavx (suzetrigine, NaV1.8 acute pain): $29M Q1 2026 (vs $1.3M PY) — first non-opioid acute pain drug.

Forward P/E ~24-26× FY26e.

Verdict — Add: Three commercial franchises (CF, sickle cell gene therapy, non-opioid pain) at scale. The cleanest biotech compounder.

REGN — Regeneron

Q1 2026: revenue $3.6B (+19% YoY). Adjusted EPS $9.47. Dupixent global net sales $4.9B (+31% CER) — ~$20B annualized. Eylea HD US $468M (+52% YoY); combined US Eylea + Eylea HD $941M (-10% YoY) — biosimilar pressure.

Eylea biosimilar threat: Amgen Pavblu launched October 2024; Samsung Bioepis Opuviz launch January 2027; Sandoz can launch by end-2026. Management expects Eylea demand to decline mid-to-high teens in Q2 2026.

MFN deal: Regeneron signed April 2026.

Forward P/E ~16-18× FY26e.

Verdict — Hold: Dupixent dominance offsets Eylea pressure but H2 2026 biosimilar wave is the bear case. Wait for the Eylea decline to stabilize before adding.

GILD — Gilead Sciences

Q1 2026: product sales $6.9B (+5%). HIV $5.0B (+10%); Biktarvy $3.4B (+7%). Yeztugo (twice-yearly lenacapavir PrEP, launched mid-2025) $166M Q1 2026 (+72% QoQ); US PrEP +87% YoY. Trodelvy $402M (+37%). Arcellx acquisition $7.8B (Feb 2026) — anito-cel BCMA CAR-T, direct Carvykti competitor.

FY 2026 guide raised: product sales $30.0-30.4B.

Forward P/E ~11-12× FY26e.

Verdict — Add: Yeztugo PrEP scale + Trodelvy expansion + Arcellx upside. Stock down 17% YoY despite Q1 beat = compelling entry point.

BMY — Bristol Myers Squibb

Q1 2026: revenue $11.49B (+2.6% YoY). Eliquis ~$4.1B (+13%). IRA Round 1: Eliquis MFP $231 (-56%) effective January 1, 2026. US generic LOE April 1, 2028. Cobenfy (schizophrenia, KarXT-derived) ramping post-launch.

Forward P/E ~8-10× FY26e — deepest value in Big Pharma reflecting Eliquis double-cliff.

Verdict — Skip: Eliquis IRA + LOE 2028 is the structural overhang. Cobenfy + Opdivo can't compensate. Cheap multiple isn't enough.

MRNA — Moderna

Q1 2026 numbers and cash burn remain consistent with the post-COVID restructuring profile. $7.5B cash end-Q1 2026; FY26 target $4.2B adjusted cash costs.

Verdict — Avoid: Cash burn relative to commercial revenue base remains structurally challenged.

---

Layer 4 — Cell/gene therapy + oncology specialty

CRSP — CRISPR Therapeutics

Casgevy with VRTX — same patient ramp story as VRTX. CRSP gets economic share but VRTX leads commercial.

CYTK — Cytokinetics

Aficamten FDA approved December 19, 2025 as MYQORZO for oHCM. MAPLE-HCM PDUFA November 14, 2026.

Verdict — Hedge: Aficamten launch is real; MYQORZO label expansion is the catalyst. Size 1-2%.

BNTX — BioNTech, EDIT/NTLA — gene editing

Speculative; pre-revenue commercial at scale.

Verdict (basket) — Skip: Better cell/gene exposure via VRTX (Casgevy) + GILD (CAR-T).

---

Layer 5 — Medical devices + diagnostics

ISRG — Intuitive Surgical

Q1 2026: revenue $2.77B (+23% YoY). da Vinci 5 placements 232 (vs 147 PY). Ion procedures continued growth.

Verdict — Core buy: Da Vinci 5 ramp is the cleanest device-cycle thesis. Premium multiple supported by visible adoption.

BSX — Boston Scientific

Q1 2026: WATCHMAN +19% organic but below expectations. FY26 guide CUT to 6.5-8%. FARAPULSE PFA growth continues.

Verdict — Hold: Guide cut is the near-term overhang but Farapulse PFA momentum continues. Wait for guide stabilization.

Others — MDT, SYK, EW, DXCM, PODD

Medtronic (Diabetes 788G, Hugo robotics); Stryker (Mako orthopedic); Edwards (TAVR + structural heart); DexCom (CGM Stelo OTC launch); Insulet (Omnipod 5).

Verdict (basket) — Hold: Each has its own merit. Tools (TMO, DHR) provide broader life-sciences exposure.

TMO — Thermo Fisher, DHR — Danaher

Life sciences tools — broader healthcare cycle exposure.

Verdict (both) — Hold: Defensive tools exposure but not 2026 acceleration stories.

---

What not to chase

• PFE for GLP-1 — Metsera 2028 launch target; better LLY/NVO/AMGN/RHHBY exposure
• BMY — Eliquis double-cliff (IRA + 2028 LOE)
• MRNA — cash burn relative to commercial base
• Lone-name gene editing bets (EDIT, NTLA) — pre-revenue; better via VRTX/GILD
• Indian-listed pharma (Sun, DRL, Cipla, etc.) — NSE-listed, out of scope for Schedule FA disclosure; for context, generic semaglutide launched in India March 2026

---

Three model portfolios

Defensive: GLP-1 leader + diversified + dividend

Bucket	Weight	Names
GLP-1 leader	25%	LLY 25%
Big Pharma	35%	JNJ 12%, ABBV 12%, AZN 11%
Biotech innovator	15%	VRTX 8%, GILD 7%
Devices	15%	ISRG 8%, BSX 4%, EW 3%
ETF	5%	XLV 5%
Cash	5%	—

Balanced: dual GLP-1 + Big Pharma + biotech + devices

Bucket	Weight	Names
GLP-1	30%	LLY 18%, NVO 7%, AMGN 5%
Big Pharma	25%	JNJ 8%, ABBV 7%, AZN 6%, SNY 4%
Biotech	20%	VRTX 8%, GILD 8%, REGN 4%
Devices	15%	ISRG 8%, BSX 4%, MDT 3%
ETF	5%	IBB 5%
Cash	5%	—

Aggressive: GLP-1 + speculative biotech + cell/gene

Bucket	Weight	Names
GLP-1	35%	LLY 18%, NVO 7%, AMGN 6%, RHHBY 4%
Biotech	30%	VRTX 12%, GILD 8%, REGN 5%, CYTK 5%
Big Pharma anchor	15%	JNJ 8%, ABBV 7%
Devices	10%	ISRG 7%, DXCM 3%
ETF	5%	XBI 5%
Cash	5%	—

---

The risk scenarios

IRA Round 2 effective January 1, 2027 hits Ozempic+Wegovy+Rybelsus -71% Medicare. NVO single biggest exposure.

Keytruda 2028 IV LOE = ~$30B+ revenue at risk for MRK. Qlex SC migration is the defense.

Trump MFN deals could become mandatory rather than voluntary. Bear case across US pricing.

April 2, 2026 100% pharma tariff effective July 31, 2026 — Indian-manufactured branded products exposed.

GLP-1 competitor wave — Roche enicepatide (2028), Amgen MariTide (2027), Pfizer Metsera (2028+).

Biosimilar erosion — REGN Eylea (multiple entrants H2 2026), MRK Keytruda (2028), JNJ Stelara (ongoing).

---

How an Indian-resident investor actually executes this

Platform map. All US-listed pharma + biotech + devices broadly available on Vested / INDmoney / IBKR / Rovia. European ADRs (NVO Denmark, AZN UK, RHHBY Switzerland, NVS Switzerland, GSK UK, SNY France) — most accessible across platforms; IBKR cleanest for direct EU listings.

Tax on gains. Foreign equity LTCG 12.5% under Section 112 with 24-month holding period.

Schedule FA. Calendar-year disclosure for any held during January-December. See Schedule FA guide.

Dividend WHT by listing. US 25% under DTAA. UK 0% (AZN, GSK) — structural advantage. Denmark 27% reducible to 15% (NVO). Switzerland 35% reducible to 10% (RHHBY, NVS). France 25% reducible to 10% (SNY). Germany 26.375% reducible to 10%.

---

The closing

The honest read on June 2026:

• IRA Round 1 took effect January 1, 2026 — 10 drugs at 38-79% discount. Round 2 with GLP-1s effective January 1, 2027.
• GLP-1 is a duopoly — LLY (Mounjaro+Zepbound $12.9B Q1 alone) and NVO (Wegovy injectable + pill). Roche/Amgen/Pfizer all 2027-2028+ launches.
• Foundayo (oral orforglipron) at $149/month self-pay is the cleanest signal of MFN/MFI deflation in real time.
• Retatrutide TRIUMPH-1 (70.3 lb) confirmed LLY's pipeline depth through 2028.
• MRK Keytruda 2028 IV LOE is the dominant Big Pharma overhang; Qlex SC migration is the defense playbook.
• Indian-listed pharma is mostly insulated from US tariffs (generics exempt) but US-listed names with India-manufactured branded products face indirect cost pressure.

Own LLY for the cleanest GLP-1 thesis. Add JNJ and ABBV for diversified large-cap. Add VRTX and GILD for biotech innovation. Hedge with AMGN MariTide and RHHBY enicepatide. Watch Round 2 IRA implementation for the next big pricing shoe to drop.

The press releases will continue to dominate the headlines.

The reimbursement-coded prior authorizations are what actually clear into commercial revenue.